Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy.

Besides traditional treatment strategies, including surgery, radiotherapy, and chemotherapy for lung cancer as the leading cause of cancer incidence and death, immunotherapy has also emerged as a new treatment strategy. The goal of immunotherapy is to stimulate the immune system responses against cancer, using various approaches such as therapeutic vaccines, monoclonal antibodies, immune checkpoint inhibitors, and T-cell therapy. Chimeric antigen receptor (CAR)-T cells, one of the most popular cancer immunotherapy approaches in the last decade, are genetically engineered T-cells to redirect patients' immune responses to recognize and eliminate tumor-associated antigens (TAA)-expressing tumor cells. CAR-T cell therapy provides promising benefits in lung tumors. In this review, we summarize different immunotherapy approaches for lung cancer, the structure of CAR-T cells, currently undergoing CARs in clinical trials, and various TAAs are being investigated as potential targets in designing CAR-T cells for lung cancer. Copyright © 2021 Elsevier Inc. All rights reserved.

Citation

Tongqing Xue, Xiang Zhao, Kun Zhao, Yan Lu, Juan Yao, Xianguo Ji. Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy. Current problems in cancer. 2022 Feb;46(1):100791

Mesh Tags

Substances

PMID: 34538649

search → result